IL145641A0 - C7 ester substituted taxanes as antitumor agents - Google Patents

C7 ester substituted taxanes as antitumor agents

Info

Publication number
IL145641A0
IL145641A0 IL14564101A IL14564101A IL145641A0 IL 145641 A0 IL145641 A0 IL 145641A0 IL 14564101 A IL14564101 A IL 14564101A IL 14564101 A IL14564101 A IL 14564101A IL 145641 A0 IL145641 A0 IL 145641A0
Authority
IL
Israel
Prior art keywords
antitumor agents
ester substituted
substituted taxanes
taxanes
ester
Prior art date
Application number
IL14564101A
Other languages
English (en)
Original Assignee
Univ Florida State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida State Res Found filed Critical Univ Florida State Res Found
Publication of IL145641A0 publication Critical patent/IL145641A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL14564101A 2000-02-02 2001-02-02 C7 ester substituted taxanes as antitumor agents IL145641A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17979400P 2000-02-02 2000-02-02
PCT/US2001/003385 WO2001057027A1 (en) 2000-02-02 2001-02-02 C7 ester substituted taxanes as antitumor agents

Publications (1)

Publication Number Publication Date
IL145641A0 true IL145641A0 (en) 2002-06-30

Family

ID=22658029

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14564101A IL145641A0 (en) 2000-02-02 2001-02-02 C7 ester substituted taxanes as antitumor agents

Country Status (35)

Country Link
US (3) US6610860B2 (de)
EP (1) EP1183253B8 (de)
JP (1) JP2003522167A (de)
KR (1) KR100784161B1 (de)
CN (1) CN1362955A (de)
AR (1) AR030188A1 (de)
AT (1) ATE396188T1 (de)
AU (1) AU776051B2 (de)
BG (1) BG65279B1 (de)
BR (1) BR0104749A (de)
CA (1) CA2368993C (de)
CO (1) CO5280224A1 (de)
CZ (1) CZ298484B6 (de)
DE (1) DE60134094D1 (de)
DK (1) DK1183253T3 (de)
ES (1) ES2307588T3 (de)
GE (1) GEP20043322B (de)
HK (1) HK1047938A1 (de)
HU (1) HUP0200917A3 (de)
IL (1) IL145641A0 (de)
MX (1) MXPA01009901A (de)
MY (1) MY137637A (de)
NO (1) NO327982B1 (de)
NZ (1) NZ514409A (de)
PL (1) PL202668B1 (de)
PT (1) PT1183253E (de)
RO (1) RO121777B1 (de)
RU (1) RU2265017C2 (de)
SA (1) SA01220045B1 (de)
SK (1) SK13712001A3 (de)
TR (1) TR200102856T1 (de)
TW (1) TWI291873B (de)
UA (1) UA75573C2 (de)
WO (1) WO2001057027A1 (de)
ZA (1) ZA200108060B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
CA2354486A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C7 ester substituted taxanes
SG125889A1 (en) * 2001-08-01 2006-10-30 Univ Florida State Res Found C7 ester subsituted taxanes
KR100819578B1 (ko) * 2001-08-01 2008-04-04 플로리다 스테이트 유니버시티 리서치 파운데이션, 인크 C7 에스테르 치환된 탁산
US20030082229A1 (en) * 2001-11-01 2003-05-01 Board Of Regents, The University Of Texas Systems Parenteral chlorambucil for treatment of malignant and autoimmune disease and methods of use
US8012950B2 (en) * 2003-08-29 2011-09-06 Wisconsin Alumni Research Foundation Method to diagnose and treat degenerative joint disease
US7745650B2 (en) 2003-09-25 2010-06-29 Tapestry Pharmaceuticals, Inc 9,10-α,α-OH-taxane analogs and methods for production thereof
EP1810968A3 (de) * 2003-09-25 2007-08-08 Tapestry Pharmaceuticals, Inc. 9, 10-a, a-OH-Taxan-Analoge und Herstellungsverfahren dafür
US7160919B2 (en) 2004-03-05 2007-01-09 Florida State University Research Foundation, Inc. C7 lactyloxy-substituted taxanes
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
CN101438252A (zh) * 2004-10-07 2009-05-20 爱莫里大学 多功能纳米粒子共轭体及其应用
EP1805192B1 (de) 2004-10-25 2012-10-17 Dekk-Tec, Inc. Salze aus isophosphoramidsenf und analoge davon als antitumormittel
US20060216767A1 (en) * 2005-03-22 2006-09-28 Saladax Biomedical Inc. Docetaxel immunoassay
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
EP1913958B1 (de) * 2006-08-03 2009-12-23 Sanofi-Aventis Antitumorale Zusammensetzungen enthaltend Acetylcyclopropyl Docetaxel und Trastuzumab
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008098138A1 (en) 2007-02-07 2008-08-14 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthetic macrocyclic compounds for treating cancer
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
AU2008236684B2 (en) 2007-04-06 2013-04-18 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
MX2011001122A (es) 2008-07-31 2011-03-29 Ziopharm Oncology Inc Sintesis y formulaciones de sales de mostaza de isofosforoamida y analogos de las mismas.
CA2753041A1 (en) 2009-02-24 2010-09-02 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
WO2011112867A1 (en) 2010-03-10 2011-09-15 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
CN103781495A (zh) 2011-07-11 2014-05-07 美国政府(由卫生和人类服务部的部长所代表) 光敏抗体-荧光团缀合物
US20150157580A1 (en) 2012-05-25 2015-06-11 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途
CN106470705B (zh) 2014-08-08 2020-03-31 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
EP3774912A1 (de) 2018-04-10 2021-02-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Kombination von nah-infrarot-fotoimmunotherapie gegen krebszellen und wirtsimmunaktivierung
KR20220031054A (ko) 2019-07-02 2022-03-11 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Egfrviii에 결합하는 단일클론 항체 및 이의 용도
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
EP4284439A1 (de) 2021-01-29 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Nahinfrarot-photoimmuntherapie-kombinationstherapie (nir-pit) zur behandlung von krebs
IL308018B2 (en) 2021-04-30 2025-04-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for altered MHC expression
WO2024006965A1 (en) 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cd25-specific antibodies and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4960790A (en) 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
SE463189B (sv) 1989-03-13 1990-10-22 Eston Joensson Preparat avsett att tillfoeras amalgamfyllningar i taender foer att daerigenom hindra eller minska avgaang av kvicksilver eller kvicksilveraanga
US5175315A (en) 1989-05-31 1992-12-29 Florida State University Method for preparation of taxol using β-lactam
FR2679230B1 (fr) 1991-07-16 1993-11-19 Rhone Poulenc Rorer Sa Nouveaux derives d'analogues du taxol, leur preparation et les compositions qui les contiennent.
US5714513A (en) 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5227400A (en) 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5243045A (en) 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5721268A (en) 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
SG46582A1 (en) 1991-09-23 1998-02-20 Univ Florida State 10-Desacetoxytaxol derivatives
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5430160A (en) 1991-09-23 1995-07-04 Florida State University Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
RU2059631C1 (ru) * 1991-11-29 1996-05-10 Дзе Юниверсити оф Канзас Производные таксола и фармацевтическая композиция, обладающая противоопухолевой активностью
EP1001036B1 (de) 1992-01-15 2004-10-20 E.R. Squibb & Sons, Inc. Enzymatische Verfahren zur Aüftrennüng von Enantiomeren-Mischungen nützlich als Zwischenprodukte zur Herstellung von Taxanen
US5272171A (en) 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
US5352806A (en) 1992-04-17 1994-10-04 Abbott Laboratories Taxol derivatives
US5248796A (en) 1992-06-18 1993-09-28 Bristol-Myers Squibb Company Taxol derivatives
US5319112A (en) 1992-08-18 1994-06-07 Virgnia Tech Intellectual Properties, Inc. Method for the conversion of cephalomannine to taxol and for the preparation of N-acyl analogs of taxol
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
CA2119261C (en) 1992-12-23 2006-01-31 Michael A. Poss Novel sidechain-bearing taxanes and intermediates thereof
IL108443A0 (en) * 1993-01-29 1994-04-12 Univ Florida State C7 taxane derivatives and pharmaceutical compositions containing them
US5703247A (en) 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
DE69425563T2 (de) * 1993-03-22 2001-01-25 Florida State University, Tallahassee Taxane mit amino-substituierter seitenkette
DE69434374T2 (de) * 1993-03-22 2005-11-24 Florida State University, Tallahassee Taxane mit Furyl oder Thienyl enthaltender substituierter Seitenkette
ATE209489T1 (de) * 1993-03-22 2001-12-15 Univ Florida State Taxane mit pyridyl-substituierter seitenkette
EP0982302B1 (de) 1993-06-11 2004-04-14 PHARMACIA & UPJOHN COMPANY Delta 6,7-Taxol Derivate antineoplastische Verwendung und diese enthaltende pharmazeutische Zusammenstellungen
IL109926A (en) 1993-06-15 2000-02-29 Bristol Myers Squibb Co Methods for the preparation of taxanes and microorganisms and enzymes utilized therein
TW397866B (en) 1993-07-14 2000-07-11 Bristol Myers Squibb Co Enzymatic processes for the resolution of enantiomeric mixtures of compounds useful as intermediates in the preparation of taxanes
FR2711369B1 (fr) 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions qui les contiennent.
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5414869A (en) * 1993-11-26 1995-05-16 Thomson; Margaret I. Knotless scarf and method of making same
FR2721024B1 (fr) * 1994-06-09 1996-07-12 Rhone Poulenc Rorer Sa Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH10508022A (ja) * 1994-10-28 1998-08-04 ザ リサーチ ファウンデーション オブ ステート ユニバーシティ オブ ニューヨーク タキソイド誘導体、それらの製造、およびそれらの抗腫瘍薬としての使用
TW354293B (en) 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
US5780653A (en) 1995-06-07 1998-07-14 Vivorx Pharmaceuticals, Inc. Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers
CA2231837A1 (en) 1995-09-13 1997-03-20 Florida State University Radiosensitizing taxanes and their pharmaceutical preparations
US5767297A (en) 1997-02-05 1998-06-16 Ensuiko Sugar Refining Co., Ltd. Taxoid derivative and method of producing thereof
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1997042181A1 (en) 1996-05-06 1997-11-13 Florida State University 1-deoxy baccatin iii, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5811452A (en) 1997-01-08 1998-09-22 The Research Foundation Of State University Of New York Taxoid reversal agents for drug-resistance in cancer chemotherapy and pharmaceutical compositions thereof
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
DE69729128T2 (de) * 1997-10-08 2005-04-28 Bio Research Corporation Of Yokohama, Yokohama Taxoid-derivate und verfahren zu ihrer herstellung
US6136988A (en) 1998-04-10 2000-10-24 Hauser, Inc. 7-hexanoyltaxol and methods for preparing the same
US5964739A (en) * 1998-06-18 1999-10-12 Champ; Raynido A. Safety disposable needle structure
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
EP1192126A1 (de) 1999-06-21 2002-04-03 Napro Biotherapeutics, Inc. An der c2-hydroxygruppe geschützte, aktivierte n-acyl(2r,3s)-3-phenylisoserinester und verfahren zu ihrer herstellung
US6348215B1 (en) * 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
US6638973B2 (en) * 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
NZ514073A (en) 2000-02-02 2004-02-27 Univ Florida State Res Found Taxane formulations having improved solubility
IT1319168B1 (it) 2000-03-17 2003-09-26 Indena Spa Derivati di condensazione ad attivita' antitumorale, loro metodo dipreparazione e formulazioni che li contengono.

Also Published As

Publication number Publication date
ES2307588T3 (es) 2008-12-01
RO121777B1 (ro) 2008-04-30
SK13712001A3 (sk) 2002-05-09
US6610860B2 (en) 2003-08-26
PL202668B1 (pl) 2009-07-31
PL350026A1 (en) 2002-10-21
KR20010111583A (ko) 2001-12-19
CA2368993A1 (en) 2001-08-09
DK1183253T3 (da) 2008-09-22
MXPA01009901A (es) 2003-07-28
TWI291873B (en) 2008-01-01
HUP0200917A2 (en) 2002-08-28
DE60134094D1 (de) 2008-07-03
NO327982B1 (no) 2009-11-02
BG65279B1 (bg) 2007-11-30
PT1183253E (pt) 2008-08-04
NZ514409A (en) 2004-03-26
BG105967A (en) 2002-08-30
HU0200917D0 (en) 2002-04-29
ZA200108060B (en) 2003-12-01
WO2001057027A1 (en) 2001-08-09
NO20014759D0 (no) 2001-10-01
CO5280224A1 (es) 2003-05-30
AU776051B2 (en) 2004-08-26
HUP0200917A3 (en) 2004-07-28
KR100784161B1 (ko) 2007-12-12
GEP20043322B (en) 2003-12-10
MY137637A (en) 2009-02-27
UA75573C2 (en) 2006-05-15
US20020013346A1 (en) 2002-01-31
CN1362955A (zh) 2002-08-07
US20070249708A1 (en) 2007-10-25
ATE396188T1 (de) 2008-06-15
EP1183253B1 (de) 2008-05-21
RU2265017C2 (ru) 2005-11-27
AU3323901A (en) 2001-08-14
BR0104749A (pt) 2001-12-26
US20040014979A1 (en) 2004-01-22
CA2368993C (en) 2009-10-20
EP1183253A1 (de) 2002-03-06
US7186849B2 (en) 2007-03-06
EP1183253B8 (de) 2009-01-07
AR030188A1 (es) 2003-08-13
TR200102856T1 (tr) 2002-06-21
SA01220045B1 (ar) 2008-06-07
JP2003522167A (ja) 2003-07-22
NO20014759L (no) 2001-11-29
CZ20013503A3 (cs) 2002-03-13
CZ298484B6 (cs) 2007-10-17
HK1047938A1 (zh) 2003-03-14

Similar Documents

Publication Publication Date Title
HU0200917D0 (en) C7 ester substituted taxanes as antitumor agents
AU1046802A (en) Polyarylcarboxamides useful as lipid lowering agents
AU7306201A (en) Substituted-triazolopyrimidines as anticancer agents
GC0000312A (en) Biphenylcarboxamides useful as lipid lowering agents
PL350075A1 (en) Taxane formulations having improved solubility
HUP0200995A3 (en) Taxane formulations having improved solubility
GB0025437D0 (en) Esters
NZ514074A (en) C10 carbonate substituted taxanes as antitumor agents
IL145637A0 (en) C7 carbonate substituted taxanes as antitumor agents
HUP0200752A3 (en) C7 carbamoyloxy substituted taxanes as antitumor agents
EP1329501A4 (de) Neue pla1
GB0025438D0 (en) Esters
HUP0103247A3 (en) C7 ester substituted taxanes
ZA200106335B (en) C7 ester substituted taxanes.
TW479555U (en) Vertical moving stage
GB0015865D0 (en) Lipid compositions
GB0027048D0 (en) Shield
GB0017074D0 (en) Ester synthesis
GB0015568D0 (en) Ester synthesis
HU0103245D0 (en) C10 ester substituted taxanes
SG129990A1 (en) C10 ester substituted taxanes
TW501728U (en) Tachometer
TW438023U (en) Improved billboard structure
TW420027U (en) Improved structure of amusement machine panel